Skip to main content
January 12, 2015

H&P Labs announces in-licensing agreement with Harvard University for compounds to develop oral Ebola treatment

MONTREAL, Jan. 8, 2014 /PRNewswire/ - H&P Labs Inc. announced an agreement with Harvard University and Brigham and Women's Hospital to license two classes of compounds in order to develop an oral drug therapy against Ebola.

These compounds were identified because they interfere with entry of Ebola virus (EboV) particles into cells. One class of compounds targets Niemann-Pick C1 (NPC1), a host protein that binds the EboV glycoprotein and is essential for infection; the other inhibits the transport of EboV particles to the cell compartment containing NPC1.

View Original Article »

Press Contact

Caroline Perry, (617) 495-4157
Email

Press Contact

Caroline Perry
(617) 495-4157
Email